Table 4.

Comparison of outcomes in APOBEC vs Other patients.

APOBEC vs. Other
Patient Group (N)	Comparison	Median Survival (months)	p-value
APOBEC (16) vs Other (56)	OS from initial diagnosis	125.3 vs 44.5	0.05
	From IO Start
APOBEC (8) vs	OS	12.4 vs 14.1	0.27
Other (25)	PFS	4.1 vs 3.3	0.25
	From Chemotherapy Start
APOBEC (5) vs	OS	7.0 vs 13.1	0.05
Other (15)	PFS	4.3 vs 7.0	0.01

HM, hypermutated; NHM, non-hypermutated; OS, overall survival; PFS, progression-free survival; IO, immunotherapy.

Bold: statistically significant.